MarketCap
Facebook
X
TelegramCountry |
 USA |
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
42.8 M |
Market Cap[1] |
$ 459 M |
EBITDA (LTM) |
$ 224 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.86 | 3.08 % | $ 807 M | Nasdaq Global Select Market |  Canada |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Aclaris Therapeutics
ACRS
|
$ 3.22 | -1.08 % | $ 249 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.05 | -7.08 % | $ 290 K | Nasdaq Capital Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.27 | -4.88 % | $ 588 M | NYSE American |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 13.58 | -3.62 % | $ 894 M | Nasdaq Capital Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 216.09 | -1.96 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.14 | -4.15 % | $ 7.55 B | Nasdaq Capital Market |  Australia |
 |
Celldex Therapeutics
CLDX
|
$ 27.1 | -1.51 % | $ 1.75 M | Nasdaq Global Select Market | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 88.16 | 0.19 % | $ 9.1 B | Nasdaq Capital Market,SPB | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 24.27 | 2.75 % | $ 2.87 B | Nasdaq Capital Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
CureVac N.V.
CVAC
|
$ 5.02 | -0.59 % | $ 934 M | Nasdaq Global Market | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
BioVie
BIVI
|
$ 1.4 | -3.45 % | $ 2.07 M | Nasdaq Capital Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | Britain |
 |
BioNTech SE
BNTX
|
$ 93.87 | -0.99 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Dynavax Technologies Corporation
DVAX
|
$ 10.8 | - | $ 1.4 B | Nasdaq Capital Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 26.2 | 3.68 % | $ 1.27 B | Nasdaq Global Select Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Anika Therapeutics
ANIK
|
$ 9.57 | 0.1 % | $ 140 M | Nasdaq Global Select Market,SPB | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 15.96 | -4.42 % | $ 409 M | Nasdaq Global Market | USA |
 |
Evogene Ltd.
EVGN
|
$ 1.07 | -0.51 % | $ 27.9 M | Nasdaq Global Market | Israel |
 |
Exelixis
EXEL
|
$ 41.43 | 1.35 % | $ 12 B | Nasdaq Global Select Market,SPB | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Axon Enterprise
AXON
|
$ 548.8 | -2.74 % | $ 41.6 B | Nasdaq Global Select Market,SPB | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
|
Foghorn Therapeutics
FHTX
|
$ 4.36 | -1.8 % | $ 239 M | Nasdaq Global Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.39 | 3.91 % | $ 15 M | Nasdaq Capital Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 91.03 | 1.34 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Burford Capital Limited
BUR
|
$ 8.85 | -1.72 % | $ 1.45 B | NYSE | Britain |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.36 | -1.47 % | $ 735 M | NYSE | USA |
 |
Biogen
BIIB
|
$ 174.34 | 0.14 % | $ 25.4 B | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.